Prostate Cancer

Active surveillance has become the treatment of choice for low-risk prostate cancer, but new tools are needed to make it more precise.

In the medical community, we know that, at a population level, active surveillance is better for certain men with prostate cancer, so we believe the benefit weighs in their favor. We would like to offer men more certainty that surveillance can work for them and hope that, in the next few years, research will bring that to pass.

Obese patients being treated for breast or prostate cancer showed higher levels of mental and physical distress than nonobese patients with these diseases, but the pattern did not hold true in those with colorectal cancer, according to a study.

A recent study found no different in disease recurrence among men with prostate cancer when they were given radiation after surgery or not.

Phase 3 trial findings showed that treatment with Lynparza delayed disease progression by about four months compared with newer hormonal agents in pre-treated patients with metastatic castration-resistant prostate cancer and faulty DNA repair genes.

Morever, the next-generation androgen receptor improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer, according to updated findings of the phase 3 SPARTAN trial.

Here is a list of the recent trial initiations that occurred within the cancer space in September.

For Prostate Cancer Awareness Month, here’s a round-up of the latest news and updates in this disease space.

Men with castration-sensitive prostate cancer now have an option for when treatment with androgen deprivation therapy alone is not enough.

A phase 3 trial showed a 33% reduction in the risk of death when patients were treated with Erleada compared with placebo.

I encourage men to be more knowledgeable of their family history and to potentially begin testing for prostate cancer earlier if you have a family history of the disease.

Here is a list of the recent trial initiations that occurred within the cancer space in August.

Following the Food and Drug Administration’s approval of Nubeqa, men with non-metastatic castration-resistant prostate cancer now have an earlier more precise treatment option.

The Food and Drug Administration granted a priority review to Nubeqa for the treatment of men with non-metastatic castration-resistant prostate cancer.

From today’s top performers and athletes to surprising findings about prostate cancer treatment, here’s what is making headlines in the cancer space this week.

One patient and a physician expert discuss a variety of topics in prostate cancer.

From Beth Chapman’s untimely passing to cancer fundraising via esports, here’s what is making headlines in the cancer space this week.

This essay was written by Dr. Kevin Yiee, CHI Health St. Elizabeth, nominating registered oncology-certified nurse Robin Devries for CURE®’s 2019 Extraordinary Healer® Award.

In this week’s episode, we spoke with a patient and his doctor about genomic testing and how it can change treatment outcomes for patients with cancer.

Thousands of men who will be diagnosed with prostate cancer this year alone now have a wealth of new and updated resources to ensure they make the best treatment choices they can.

A good nurse can make a huge difference for a patient struggling to deal with an illness, not only in comfort, or pain relief, or even in teaching how to manage symptoms or side effects – but in hope and confidence.

The Prostate Cancer Foundation announced the newly revised 2019 Prostate Cancer Patient Guide, a comprehensive resource for diagnosis, treatment, side effects, survivorship, and risk factors for patients and families with a history of prostate cancer.